WEBULL
News
KRYS
254.36
+0.26%
0.67
Weekly Report: what happened at KRYS last week (0302-0306)?
Weekly Report · 10h ago
Top Krystal Biotech Insiders Just Cashed In Big on Their Shares
TipRanks · 2d ago
Krystal Biotech Files Initial Beneficial Ownership Statement for EVP, Head of International Laurent Louis Jean Goux
Reuters · 2d ago
Krystal Biotech Files Initial Beneficial Ownership Statement for EVP, General Counsel John Charles Thomas
Reuters · 2d ago
Krystal Biotech President, R&D Suma Krishnan Disposes of Common Shares
Reuters · 2d ago
Krystal Biotech CEO Krish S. Krishnan Disposes of Common Shares
Reuters · 2d ago
Krystal Biotech Chief Accounting Officer Kathryn Romano Disposes of Common Shares
Reuters · 5d ago
Krystal Biotech Director Daniel Janney Disposes of Common Shares
Reuters · 5d ago
Weekly Report: what happened at KRYS last week (0223-0227)?
Weekly Report · 03/02 10:18
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed?
Simply Wall St · 02/27 12:38
Top Krystal Biotech Insider Offloads a Massive Stake in High-Value Stock Move
TipRanks · 02/27 02:01
Krystal Biotech Director Daniel Janney Disposes of Common Shares
Reuters · 02/26 23:50
Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone
Simply Wall St · 02/26 04:52
Krystal Biotech Is Maintained at Buy by Guggenheim
Dow Jones · 02/25 14:31
Krystal Biotech Price Target Raised to $284.00/Share From $224.00 by Guggenheim
Dow Jones · 02/25 14:31
Guggenheim Maintains Buy on Krystal Biotech, Raises Price Target to $284
Benzinga · 02/25 14:23
Krystal Biotech price target raised to $284 from $224 at Guggenheim
TipRanks · 02/25 12:03
Krystal Biotech RMAT Win Shifts Focus To Broader Gene Therapy Pipeline
Simply Wall St · 02/24 20:26
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
Reuters · 02/24 13:01
Krystal Biotech Director Dino A. Rossi Disposes of Common Shares
Reuters · 02/24 00:15
More
Webull provides a variety of real-time KRYS stock news. You can receive the latest news about Krystal Biotech through multiple platforms. This information may help you make smarter investment decisions.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.